{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:49:08Z","timestamp":1784958548089,"version":"3.55.0"},"reference-count":62,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Chronic myeloid neoplasms are clonal diseases with variable clinical course and outcomes and despite the introduction of novel therapies, patients with high-risk disease continue to have overall poor outcomes. Different groups have highlighted that men have overall worse survival and higher incidence of transformation to acute leukemia compared to women across neoplasms such as myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), MDS\/MPN overlap neoplasms, and CML. More recent studies evaluating the genomic profile of patients with these neoplasms demonstrated a male predominance for mutations in high-risk genes including ASXL1, U2AF1, SRSF2 and ZRSR2. The understanding of the underlying biology is limited but a number of hypotheses have been developed and are currently being investigated. This review summarizes the current knowledge about sex-related differences in the clinical outcomes and genomic profile of patients with chronic myeloid neoplasms and discusses the hypothesized biologic mechanisms as an attempt to explain these observations.<\/jats:p>","DOI":"10.3390\/ijms22052595","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:39:07Z","timestamp":1614904747000},"page":"2595","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Sex-Related Differences in Chronic Myeloid Neoplasms: From the Clinical Observation to the Underlying Biology"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6792-8298","authenticated-orcid":false,"given":"Theodoros","family":"Karantanos","sequence":"first","affiliation":[{"name":"Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Jain","sequence":"additional","affiliation":[{"name":"Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8673-4317","authenticated-orcid":false,"given":"Alison R.","family":"Moliterno","sequence":"additional","affiliation":[{"name":"Division of Adult Hematology, Department of Medicine, Johns Hopkins University, Baltimore, MD 21231, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[{"name":"Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"DeZern","sequence":"additional","affiliation":[{"name":"Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc.2016.112","article-title":"The genetics of myelodysplastic syndrome: From clonal haematopoiesis to secondary leukaemia","volume":"17","author":"Sperling","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.2009.21.8073","article-title":"Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia","volume":"28","author":"Lim","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3324\/haematol.2016.149559","article-title":"Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: An analysis by the MPN QOL International Working Group","volume":"102","author":"Geyer","year":"2017","journal-title":"Haematologica"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.7150\/jca.28220","article-title":"Gender disparity in the survival of patients with primary myelodysplastic syndrome","volume":"10","author":"Wang","year":"2019","journal-title":"J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1182\/bloodadvances.2019001407","article-title":"Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden","volume":"4","author":"Karantanos","year":"2020","journal-title":"Blood Adv."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1080\/10428194.2016.1246726","article-title":"Differential response to hypomethylating agents based on sex: A report on behalf of the MDS Clinical Research Consortium (MDS CRC)","volume":"58","author":"DeZern","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"De-Morgan, A., Meggendorfer, M., Haferlach, C., and Shlush, L. (2020). Male predominance in AML is associated with specific preleukemic mutations. Leukemia.","DOI":"10.1038\/s41375-020-0935-5"},{"key":"ref_9","first-page":"3198","article-title":"Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index","volume":"50","author":"Ossenkoppele","year":"2014","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.26050","article-title":"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/sj.leu.2403756","article-title":"Gender aspects in chronic myeloid leukemia: Long-term results from randomized studies","volume":"19","author":"Berger","year":"2005","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.stem.2018.01.011","article-title":"Clonal hematopoiesis and evolution to hematopoietic malignancies","volume":"22","author":"Bowman","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1200\/EDBK_239083","article-title":"CHIP, CCUS, and other acronyms: Definition, implications, and impact on practice","volume":"39","author":"DeZern","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Li, X., Xiao, Z.J., Chang, C.K., Xu, F., Wu, L.Y., He, Q., Xu, Z.F., Song, L.X., Zhang, Z., and Zhou, L.Y. (2013). Distinct clinical and experimental characteristics in the patients younger than 60 years old with myelodysplastic syndromes. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0057392"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/annonc\/mdp264","article-title":"Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes","volume":"21","author":"Germing","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/10428194.2017.1357179","article-title":"Myelodysplastic and myeloproliferative neoplasms: Updates on the overlap syndromes","volume":"59","author":"Thota","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","article-title":"Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)","volume":"31","author":"Mesa","year":"2007","journal-title":"Leuk. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"874146","DOI":"10.1155\/2011\/874146","article-title":"Gender and vascular complications in the JAK2 V617F-Positive myeloproliferative neoplasms","volume":"2011","author":"Stein","year":"2011","journal-title":"Thrombosis"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41408-018-0128-x","article-title":"Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: Results from the MYSEC project","volume":"8","author":"Barraco","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ajh.24882","article-title":"Gender and survival in essential thrombocythemia: A two-center study of 1494 patients","volume":"92","author":"Tefferi","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V66.6.1352.1352","article-title":"Prognostic discrimination among younger patients with chronic granulocytic leukemia: Relevance to bone marrow transplantation","volume":"66","author":"Sokal","year":"1985","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/ajh.25306","article-title":"Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY","volume":"94","author":"Hehlmann","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/eurheartj\/ehz591","article-title":"Clonal haematopoiesis in patients with degenerative aortic valve stenosis undergoing transcatheter aortic valve implantation","volume":"41","author":"Hoffmann","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2018-05-848473","article-title":"Mutational landscape of myelodysplastic\/myeloproliferative neoplasm-unclassifiable","volume":"132","author":"Bose","year":"2018","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: An international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2016-01-693879","article-title":"Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia","volume":"128","author":"Metzeler","year":"2016","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Engen, C.B.N., Grob, T., Lowenberg, B., Valk, P., and Gjertsen, B.T. (2021). Sex disparity in acute myeloid leukemia\u2014Evidence from a study of FLT3-ITD mutated patients. medRxiv.","DOI":"10.1101\/2020.09.04.20188219"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10654-011-9647-5","article-title":"Enigmatic sex disparities in cancer incidence","volume":"27","author":"Edgren","year":"2012","journal-title":"Eur. J. Epidemiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1054\/bjoc.1999.0904","article-title":"Gender differences in lung cancer risk by smoking: A multicentre case-control study in Germany and Italy","volume":"82","author":"Kreuzer","year":"2000","journal-title":"Br. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J. Clin."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00439-011-0994-9","article-title":"X-chromosome inactivation: Molecular mechanisms from the human perspective","volume":"130","author":"Yang","year":"2011","journal-title":"Hum. Gen."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Berletch, J.B., Ma, W., Yang, F., Shendure, J., Noble, W.S., Disteche, C.M., and Deng, X. (2015). Escape from X inactivation varies in mouse tissues. PLoS Gen., 11.","DOI":"10.1371\/journal.pgen.1005079"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nrc1413","article-title":"X-chromosome genetics and human cancer","volume":"4","author":"Spatz","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/ng.3726","article-title":"Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias","volume":"49","author":"Dunford","year":"2017","journal-title":"Nat. Gen."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Togami, K.C.S., Madan, V., Kenyon, C.M., Cabal-Hierro, L., Taylor, J., Kim, S., Griffin, G., and Ghandi, M. (2021). Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis. bioRxiv.","DOI":"10.1101\/2020.10.29.360503"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood-2018-03-785915","article-title":"How I treat MDS after hypomethylating agent failure","volume":"133","author":"Santini","year":"2019","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0092-8674(83)90327-6","article-title":"On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs","volume":"33","author":"Santi","year":"1983","journal-title":"Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/0006-2952(65)90175-9","article-title":"Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity","volume":"14","author":"Camiener","year":"1965","journal-title":"Biochem. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/rcm.2423","article-title":"Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2\u2032-deoxycytidine) by a new liquid chromatography\/tandem mass spectrometry quantification method","volume":"20","author":"Liu","year":"2006","journal-title":"Rapid Commun. Mass Spectrom. RCM"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1158\/1078-0432.CCR-12-1722","article-title":"Increased CDA expression\/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy","volume":"19","author":"Mahfouz","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.2019004143","article-title":"Oral cedazuridine\/decitabine for MDS and CMML: A phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study","volume":"136","author":"Griffiths","year":"2020","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/cas.14270","article-title":"Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes","volume":"111","author":"Jiang","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"18622","DOI":"10.1038\/s41598-020-74744-z","article-title":"Differential U2AF1 mutation sites, burden and co-mutation genes can predict prognosis in patients with myelodysplastic syndrome","volume":"10","author":"Wang","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"37239","DOI":"10.18632\/oncotarget.16744","article-title":"The relevance of a low JAK2V617F allele burden in clinical practice: A monocentric study","volume":"8","author":"Perricone","year":"2017","journal-title":"Oncotarget"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/2040620710394474","article-title":"JAK2 Allele burden in the myeloproliferative neoplasms: Effects on phenotype, prognosis and change with treatment","volume":"2","author":"Vannucchi","year":"2011","journal-title":"Ther. Adv. Hematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"8589","DOI":"10.1073\/pnas.1407688111","article-title":"Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers","volume":"111","author":"Xu","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.exphem.2010.09.008","article-title":"Disease burden at the progenitor level is a feature of primary myelofibrosis: A multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients","volume":"39","author":"Stein","year":"2011","journal-title":"Exp. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3324\/haematol.2009.014407","article-title":"Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders","volume":"95","author":"Stein","year":"2010","journal-title":"Haematologica"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/j.ygeno.2019.11.005","article-title":"The androgen receptor expression and association with patient\u2019s survival in different cancers","volume":"112","author":"Hu","year":"2020","journal-title":"Genomics"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Piezzo, M., Cocco, S., Caputo, R., Cianniello, D., Gioia, G.D., Lauro, V.D., Fusco, G., Martinelli, C., Nuzzo, F., and Pensabene, M. (2020). Targeting cell cycle in breast cancer: CDK4\/6 inhibitors. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186479"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.celrep.2017.01.072","article-title":"Targeting DNA damage response in prostate cancer by inhibiting androgen receptor-CDC6-ATR-Chk1 signaling","volume":"18","author":"Karanika","year":"2017","journal-title":"Cell Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"106681","DOI":"10.1016\/j.vph.2020.106681","article-title":"Targeting androgen receptor in macrophages inhibits phosphate-induced vascular smooth muscle cell calcification by decreasing IL-6 expression","volume":"130","author":"Pang","year":"2020","journal-title":"Vasc. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.stem.2014.11.002","article-title":"Estrogen signaling selectively induces apoptosis of hematopoietic progenitors and myeloid neoplasms without harming steady-state hematopoiesis","volume":"15","author":"Arranz","year":"2014","journal-title":"Cell Stem Cell"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1084\/jem.20082521","article-title":"Neutropenia with impaired host defense against microbial infection in mice lacking androgen receptor","volume":"206","author":"Chuang","year":"2009","journal-title":"J. Exp. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/5\/2595\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:33:09Z","timestamp":1760160789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/5\/2595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,5]]},"references-count":62,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["ijms22052595"],"URL":"https:\/\/doi.org\/10.3390\/ijms22052595","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,5]]}}}